Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Status:
Withdrawn
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of intravitreal aflibercept injections
administered in a treat and extend fashion in eyes that have persistent center involved
diabetic macular edema following at least 4 intravitreal injections of 0.3 mg ranibizumab
over 24 weeks.